Helicobacter pylori (H. pylori), a gram-negative bacterium, 1 was first isolated from humans in 1982. H. pylori infection is one of the most common infections in humans, with estimated 2 50% of the world population being infected. The infection is strongly associated with chronic gastritis, peptic ulcer, 3 adenocarcinoma and non-Hodgkin's lymphoma of stomach. An infected individual has an estimated lifetime risk of 10-20% for the development of peptic ulcer disease, which is at least 3-4 folds higher than in non-infected subjects, and <1% 
Practice points
The prevalence of infection is high in developing countries, demanding a reliable diagnosis and treatment method.
The monoclonal stool antigen test is easy and quick to use, non-invasive and does not require any special technology.
In the present study, the monoclonal SAT revealed 92.3% sensitivity and specificity of 100% before treatment, and 100% sensitivity and 100% specificity after treatment.
Based on this performance, the monoclonal SAT can be used for screening H. pylori infection and assessing efficacy of treatment in the healthcare settings of Bangladesh. Patients were diagnosed by clinical history and subsequent rate. In Pakistan, the infection rate with H. Pylori was about endoscopic findings and a total of 89 peptic ulcer patients 83% in adult patients undergoing upper GI endoscopy for 7 were recruited for the study. Three biopsy samples were various reasons. 
Monoclonal SAT for H. pylori
In recent years a new diagnostic tool, the stool antigen test, Monoclonal SAT (Premier, Platinum HpSA PLUS, has been available and the main advantages are the nonMeridian Bioscience, Italy), a commercially available invasive nature of this procedure and patients can obtain a enzyme immunoassay kit, was used to detect H. pylori stool sample at home for laboratory analysis. It is very rapid antigens present in human stool. It utilizes a plurality of and easy test and can be used in a situation where the culture monoclonal and H. pylori capture antibodies adsorbed to facilities are not available. Result can be given to a patient microwells. within 2 hours after stool collection so that prompt therapy can be introduced. The first commercially available stool test Statistical analysis was based on polyclonal antibodies and has been thoroughly All statistical analyses were performed using the Statistical evaluated with reports of a sensitivity in the range of 86- 17 18 Package for the Social Sciences, version 16.0 (SPSS, Inc, 100% and a specificity of 70-100%. A second generation of Chicago, IL). Descriptive data are given as frequencies and kits, based on monoclonal antibodies, has already been used percentages. Differences in distributions were analyzed by for several years. Though the results on monoclonal stool chi square test. The level of significance was set at P<0.05. antigen test (SAT) were not satisfactory in study conducted by 19 20 21 Quesada 27, 28 performed even in small laboratories. However, the status and ethnic background of the patients. The present accuracy of stool antigen tests in different clinical situations study also demonstrated that monoclonal SAT was positive [29] [30] [31] and outside of controlled studies is a matter of concern. in 92.3% H. pylori positive status which is similar to the 32 16 studies conducted in Turkey (92%), Norway (98.1%) and Table 3 : Stool Antigen test and H. pylori status of the study 35 in Malaysia (97.8%). We found 7.7% showed false population before treatment 16 negative results and no false positive results. Asfeldt et al. identified 5.8% false negative and 1.8% false positive result. The reasons for false negative might be due to decreased bacterial density accompanied by low H. pylori stool antigen optical density leading to an erroneous diagnosis, and high genetic variability of bacterium leading to high variability of antigenic epitopes.
Sensitivity of monoclonal stool antigen for H. pylori in this
In the present study, 87.6% of patients with peptic ulcers study before treatment was 92.31% and specificity 100%. were found to be H. pylori positive before treatment which 16 35 Asfeldt et al. and Bhewa et al. reported higher corresponds to the findings (86.2%) of a study conducted by 36 32 monoclonal SAT sensitivity and specificity. Gisbert et al. Karahan et al. in Turkey. This is in contrast to lower carried out a systematic review and meta-analysis on the detection rate of 44.2% H. pylori positive cases by Asfeldt et Bangladesh, the country with the lowest incidence of gastric cancer, and Japan, the country with the highest In this study, 9.6% were found to be H. pylori positive 4 incidence. 
